Gilead Sciences (GILD) is an American biopharmaceutical company that discovers, develops and commercializes therapeutics. For many years since the company was founded, the company concentrated primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza. In 2006, Gilead acquired two companies which were developing drugs to treat patients with pulmonary diseases. The company's current commercially available products include Atripla, Complera, Emtriva, Viread, Tybost, Vitekta, Truvada, Stribild, Harvoni, Hepsera, Sovaldi, Zydelig,Letairis, Lexiscan, Ranexa, Cayston, Tamiflu, AmBisome, and Macugen. Headquartered and founded in Foster City, California, Gilead has operations in North America, Europe and Australia. As of the end of 2015, the company had approximately 7,900 full-time employees. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500. The company's name and logo refer to the Balm of Gilead, inspired by a 1965 play by Lanford Wilson featuring the underworld adventures of the patrons of the namesake cafe.
Reported after close today (4/28/16) Earnings: EPS $3.03 Revenue $7.8B Estimates: EPS $3.13 Revenue $8.08B Down 6.07% in after hours so far
GILD revenues from its Hep C drugs fell 5.6% in the first quarter as sales of Harvoni and Sovaldi fell short of expectations. Down AH -7% !
If you are are pushing GILD to make a highly accretive acq, it will not be cheap even at these prices. Be really careful what you wish for.
Reported after close today (7/25/16) Earnings: EPS $3.08 Revenue $7.78B Estimates: EPS $3.02 Revenue $7.79B Down 3.90% after hours
Bears, you will win today but if it's EOD price @ $85 or higher, we could see $92 @ the EOW thanks 2 Fed Reserve not raising rates.
Analyst Upgrade/Downgrade Update Brokerage firm: Stifel Change: Coverage Initiated Previous Rating: N/A Current Rating: Buy Previous Price Target: N/A Current Price Target: $100
Not many investors would argue that Gilead Sciences, Inc. (NASDAQ:GILD) has been beaten down over the last two years. After all, in 2015 the stock traded as high as $123.00, but now trades at $72.00. Most investors are fearful of bottom fishing but I have made millions off of it. The key is being patient and letting the stock chart tell YOU when to buy. Too many investors force their personal views on a stock and the stock just takes all their money. In the case of Gilead Sciences, the stock may be starting to alert us to a buying opportunity. Notice on the stock chart how Gilead had a big pop starting in early November, the first big one in a long time and has since slowly settled back down, falling towards the lows. The key for me to buy is seeing if the previous low can hold. In other words, I do not want to see this slow grind lower take out the $71 level,making a higher low. If it can hold and the stock starts to inch up, I am a strong buyer. Pay attention, these types of trades can make you a lot of money.
Biotechnology stocks have been weak the last few days, and let's be honest, all of 2016. An attack by Donald Trump on drug prices did the trick over the last few days, punishing a majority of biotechnology and pharma plays. One stock that did not fall? Gilead Sciences, Inc. (NASDAQ:GILD). Last Thursday, Gilead did hit a new 52 week low. However, during that session it also reversed back to the upside. The reversal off a new 52 week low caused a bullish bottoming tail formation. This is a buy signal by itself but now Gilead Sciences has followed it up with something even better. Friday and Monday saw upside even when the Biotech Index was down. This confirms the bottom and signals major upside to smart investors. This is a strong buy with an upside target of $88.00.
Should You Buy GILD Stock After The Recent Decline? Gilead Sciences Inc http://amigobulls.com/articles/buy-gild-stock-recent-decline-gilead-sciences-inc
Many investors and analysts alike have been trying to pick a bottom in the stock this year, but the stock stubbornly continues to trade below $75 a share. Worrying downward trends with respect to the company's HCV division remain the dominant theme among investors.
This week we find out if we are going to the 50s or 80s all eyes on HIV. Needs to take the lead or it's done for a while.
